Suppr超能文献

用于治疗新冠肺炎的抗病毒药物再利用:合成、感染机制与临床试验

Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.

作者信息

Paul Subha Sankar, Biswas Goutam

机构信息

Nanyang Technological University, Singapore.

Department of Chemistry, Cooch Behar Panchanan Barma University, Panchanan Nagar, Cooch Behar 736101, India.

出版信息

Mini Rev Med Chem. 2021;21(9):1123-1143. doi: 10.2174/1389557521666201222145842.

Abstract

COVID-19 is a public health emergency of international concern. Although considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2 to date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir, which have shown promising results in different advanced stages of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir- Ritonavir combination, although initially were hypothesized to be effective against SARSCoV- 2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action, and clinical trial results available on Google and in different peer-reviewed journals till 24th October 2020.

摘要

新型冠状病毒肺炎(COVID-19)是一项国际关注的突发公共卫生事件。尽管随着时间的推移,人们已经对病毒的感染机制和复制模式有了相当多的了解,但迄今为止,尚未发现针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的特效药物或疫苗。有少数小分子抗病毒药物,如瑞德西韦和法匹拉韦,在不同的临床试验后期阶段显示出了有希望的结果。氯喹、羟氯喹以及洛匹那韦-利托那韦组合,尽管最初被假定对SARS-CoV-2有效,但现在已从团结临床试验中停用。本综述简要介绍了它们的化学合成方法、作用方式以及截至2020年10月24日在谷歌和不同同行评审期刊上可获得的临床试验结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验